Cabotegravir clinical trials
Also written GSK1265744, Apretude and Vocabria.
Counted the way a researcher would: Cabotegravir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses cabotegravir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cabotegravir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Jan 2021 · VOCABRIA · NDA 212887 (FDA, Drugs@FDA)
- European Union
- 17 Dec 2020 · Vocabria · EMEA/H/C/004976 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
59 studies that test it; most in 2020 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 40 · Other 20
ViiV Healthcare (37) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · GlaxoSmithKline (2) · Beth Israel Deaconess Medical Center (1) · University of Witwatersrand, South Africa (1) · University of California, San Francisco (1) · Janssen Research & Development, LLC (1) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1)
Often tested with
Tested in the same studies.
Rilpivirine (8) · Tenofovir (2) · Emtricitabine (2) · Dolutegravir (2) · Lamivudine (1) · Rifabutin (1) · Midazolam (1) · Lenacapavir (1)
Related medicines
As reviewed, each with the page that says it.
- One of Integrase inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Cabotegravir is the comparator. A study of two new drugs counts under both.
- 1Lenacapavir · Gilead Sciences · next primary completion Mar 2029
- 1Teropavimab · Gilead Sciences · next primary completion Mar 2029
- 1Zinlirvimab · Gilead Sciences · next primary completion Mar 2029
Reaching primary completion within a year · 2
Studies that test cabotegravir.
- Mar 2027A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsPhase 1 · ViiV Healthcare
- Aug 2027Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in BotswanaPhase 4 · Beth Israel Deaconess Medical Center
Studies
Open first, then newest update. How each study uses cabotegravir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 60
- People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for EffectivenessNot yet recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07939529Written as Cabotegravir
- NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral SettingsNot yet recruitingPhase 4Duke UniversityNCT06854029Written as Cabotegravir Injection
- Cabotegravir-Hormone PK/PD Interactions for HIV PreventionRecruitingPhase 1Johns Hopkins UniversityNCT07672717Written as Cabotegravir Injectable Suspension (CAB LA)
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTRecruitingPhase 3Africa Health Research InstituteNCT06250504Written as APRETUDE (cabotegravir) 600 mg\3 mL
- A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1RecruitingPhase 1/2ViiV HealthcareNCT07275606Written as Oral CAB
- Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject DrugsRecruitingPhase 4Massachusetts General HospitalNCT07199335Written as APRETUDE (cabotegravir)
- The Implementation of Pre-exposure Prophylaxis of Injectable CabotegravirRecruitingPhase 3Evandro Chagas National Institute of Infectious DiseaseNCT05515770Written as Cabotegravir Injection
- Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.Not yet recruitingPhase 3ANRS, Emerging Infectious DiseasesNCT06273943Written as Cabotegravir Tablets, for oral use.
- Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan AfricaNot yet recruitingPhase 3MRC/UVRI and LSHTM Uganda Research UnitNCT06133686Written as Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingPhase 3ViiV HealthcareNCT02951052Written as Cabotegravir (CAB) tablet
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsActive, not recruitingPhase 1ViiV HealthcareNCT06786520Written as CAB LA
- Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)Active, not recruitingPhase 3ViiV HealthcareNCT06134362Written as CAB LA
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsActive, not recruitingPhase 3ViiV HealthcareNCT03299049Written as Cabotegravir Tablets
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)Active, not recruitingPhase 2ViiV HealthcareNCT06741397Written as CAB LA
- A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE TerritoriesCompletedPhase 4ViiV HealthcareNCT05514509Written as APRETUDE
- SEARCH CAB LA Dynamic Choice HIV Prevention Study ExtensionCompletedPhase 4University of California, San FranciscoNCT05549726Written as Cabotegravir Injectable Suspension
- The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifECompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03635788Written as Oral CAB
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive, not recruitingPhase 3ViiV HealthcareNCT02938520Written as Cabotegravir (CAB) tablet
- Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in BotswanaActive, not recruitingPhase 4Beth Israel Deaconess Medical CenterNCT05986084Written as Cabotegravir Injection [Apretude]
- Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsCompletedPhase 1ViiV HealthcareNCT04484337Written as Cabotegravir sodium (Oral Lead In)
See all 60 studies that test cabotegravir →
Given beside what is tested · 4 — cabotegravir is usual care or a partner of the new treatment
- A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsRecruitingPhase 1ViiV HealthcareNCT05418868Written as Cabotegravir 200 mg/mL
- A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Active, not recruitingPhase 2ViiV HealthcareNCT05996471Written as Cabotegravir
- Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03739996Written as Oral Cabotegravir (CAB)
- A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese MenCompletedPhase 1ViiV HealthcareNCT03422172Written as CAB LA
As the comparator · 2 — what is tested is compared with cabotegravir
- A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedRecruitingPhase 3ViiV HealthcareNCT07650916Written as CAB LA
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyRecruitingPhase 3Gilead SciencesNCT07682961Written as Cabotegravir
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call cabotegravir · ClinicalTrials.gg INT006392
- MeSH (NLM) C584914cabotegravirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) HMH0132Z1QCABOTEGRAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 2475077One source FDA
- Wikidata Q15411012cabotegravirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169820CabotegravirOne source FDA
- DrugBank DB11751One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584914 | cabotegravir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | HMH0132Z1Q | CABOTEGRAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2475077 | — | One source FDA |
| Wikidata | Q15411012 | cabotegravir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169820 | Cabotegravir | One source FDA |
| DrugBank | DB11751 | — | One source Wikidata |
Also registered as cabotegravir sodium (UNII 3L12PT535M · RxNorm 2475076).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.